HeXun Biosciences Co., Ltd. (TPEX:6986)
Taiwan · Delayed Price · Currency is TWD 42.90
-0.05 (-0.12%)
Aug 19, 2026, 1:30 PM CST
HeXun Biosciences Revenue
HeXun Biosciences had revenue of 93.86M TWD in the quarter ending June 30, 2026, with 23.99% growth. This brings the company's revenue in the last twelve months to 308.21M, up 1.24% year-over-year. In the year 2025, HeXun Biosciences had annual revenue of 293.23M with 2.38% growth.
Revenue (ttm)
308.21M
Revenue Growth
+1.24%
P/S Ratio
7.26
Revenue / Employee
n/a
Employees
53
Market Cap
2.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 293.23M | 6.81M | 2.38% |
| Dec 31, 2024 | 286.42M | 155.85M | 119.36% |
| Dec 31, 2023 | 130.57M | 81.10M | 163.95% |
| Dec 31, 2022 | 49.47M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sunny Pharmtech | 253.01M |
| G&E Herbal Biotechnology | 215.61M |
| Gwo Xi Stem Cell Applied Technology Co. , | 187.02M |
| Intech Biopharm | 48.55M |
| GlycoNex Incorporation | 22.21M |
| BRIM Biotechnology | 10.60M |